http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108137614-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2016-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108137614-B |
| titleOfInvention | Fused pyrimidine compound, composition containing compound and application of compound |
| abstract | The invention discloses a condensed pyrimidine compound shown as a formula (I), and preparation and application thereof. Specifically, the invention discloses a condensed pyrimidine compound shown as a formula (I), or a polymorphism, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, an isotopic variant, a hydrate or a solvate thereof, a pharmaceutical composition containing the same and application thereof. The condensed pyrimidine compound and the composition containing the compound disclosed by the invention have excellent inhibition on protein kinase, and simultaneously have better pharmacokinetic parameter characteristics, and can improve the drug concentration of the compound in an animal body so as to improve the curative effect and safety of the drug. |
| priorityDate | 2015-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 199.